Generated record quarterly net revenues of $148.3 million, representing year-over-year growth of 12.5%, and record Purified Cortrophin® Gel net ...

Ani Pharmaceuticals ( (ANIP) ) has released its Q3 earnings. Here is a breakdown of the information Ani Pharmaceuticals presented to its ...

ANIP may be acquired soon with a potential offer exceeding $8 billion and contingent on FDA approval of a new drug filed in ...

ANI’s Estradiol Gel ... including statements regarding the benefits of the acquisition of Alimera Sciences. These forward-looking statements generally are identified by the words “believe ...

Update 2:40pm: Adds ANI Pharma response, updates shares. Alimera Sciences (NASDAQ:ALIM) pared an earlier drop to 6% after it said it filed a lawsuit against ANI Pharmaceuticals (ANIP) to compel ...

ANI’s Estradiol Gel ... including statements regarding the benefits of the acquisition of Alimera Sciences. These forward-looking statements generally are identified by the words ...

ANI is focused on delivering sustainable growth by scaling up ... including statements regarding the benefits of the acquisition of Alimera Sciences. These forward-looking statements generally are ...

ANI’s Estradiol Gel, 0.06% is the generic version of the reference ... including statements regarding the benefits of the acquisition of Alimera Sciences. These forward-looking statements generally ...

For Q3, investors will be centered on the Alimera (ALIM) acquisition following its delayed closure, and the firm’s main spotlight during the earnings call will be on the FDA warning letter ...